Logo image of TRIL

Trillium Therapeutic (TRIL) Stock Fundamental Analysis

NASDAQ:TRIL - Nasdaq -

18.44  +0.47 (+2.62%)

After market: 18.47 +0.03 (+0.16%)

Fundamental Rating

2

TRIL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. TRIL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TRIL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TRIL had negative earnings in the past year.
TRIL Yearly Net Income VS EBIT VS OCF VS FCFTRIL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 -20M -40M -60M

1.2 Ratios

Industry RankSector Rank
ROA -21.06%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRIL Yearly ROA, ROE, ROICTRIL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 1K 2K 3K 4K 5K

1.3 Margins

TRIL does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -139737.5%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRIL Yearly Profit, Operating, Gross MarginsTRIL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 -10K -20K -30K -40K

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, TRIL has more shares outstanding
There is no outstanding debt for TRIL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TRIL Yearly Shares OutstandingTRIL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 20M 40M 60M 80M 100M
TRIL Yearly Total Debt VS Total AssetsTRIL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 100M 200M 300M

2.2 Solvency

An Altman-Z score of 51.06 indicates that TRIL is not in any danger for bankruptcy at the moment.
TRIL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 51.06
ROIC/WACCN/A
WACCN/A
TRIL Yearly LT Debt VS Equity VS FCFTRIL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 100M 200M

2.3 Liquidity

TRIL has a Current Ratio of 12.04. This indicates that TRIL is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 12.04 indicates that TRIL has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 12.04
Quick Ratio 12.04
TRIL Yearly Current Assets VS Current LiabilitesTRIL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.93% over the past year.
TRIL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -66.67%.
EPS 1Y (TTM)52.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.33%
Revenue 1Y (TTM)-66.67%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TRIL is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.32% yearly.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-9.05%
EPS Next 2Y-2.87%
EPS Next 3Y-1.35%
EPS Next 5Y-1.32%
Revenue Next Year-96.9%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

TRIL Yearly Revenue VS EstimatesTRIL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 50K 100K 150K
TRIL Yearly EPS VS EstimatesTRIL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TRIL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRIL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRIL Price Earnings VS Forward Price EarningsTRIL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -29.43
TRIL Per share dataTRIL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.87%
EPS Next 3Y-1.35%

More info and screens

0

5. Dividend

5.1 Amount

TRIL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Trillium Therapeutic

NASDAQ:TRIL (11/16/2021, 8:19:29 PM)

After market: 18.47 +0.03 (+0.16%)

18.44

+0.47 (+2.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-15 2021-11-15
Earnings (Next)03-17 2022-03-17/amc
Inst Owners4.25%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.93B
Analysts78
Price Target15.2 (-17.57%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 48338.29
P/FCF N/A
P/OCF N/A
P/B 7.95
P/tB N/A
EV/EBITDA -29.43
EPS(TTM)-0.79
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS2.32
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -139737.5%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.04
Quick Ratio 12.04
Altman-Z 51.06
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.33%
EPS Next Y-9.05%
EPS Next 2Y-2.87%
EPS Next 3Y-1.35%
EPS Next 5Y-1.32%
Revenue 1Y (TTM)-66.67%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-96.9%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A